# EDGAR Filing Document

**Accession Number:** 0001671584
**File Stem:** 0000000000-25-005902
**Filing Date:** 2025-6
**Character Count:** 2308
**Document Hash:** 0ceb296ea733995e8d778b2f6fcbfe99
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-25-005902.hdr.sgml**: 20250718

**ACCESSION NUMBER**: 0000000000-25-005902

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250604

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Aptevo Therapeutics Inc.
- **CENTRAL INDEX KEY:** 0001671584
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 811567056
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 377-08065

**BUSINESS ADDRESS:**
- **STREET 1:** 2401 4TH AVE.
- **STREET 2:** SUITE 1050
- **CITY:** SEATTLE
- **STATE:** WA
- **ZIP:** 98121
- **BUSINESS PHONE:** 206-838-0500

**MAIL ADDRESS:**
- **STREET 1:** 2401 4TH AVE.
- **STREET 2:** SUITE 1050
- **CITY:** SEATTLE
- **STATE:** WA
- **ZIP:** 98121
**PUBLIC REFERENCE ACCESSION NUMBER**: 0000950123-25-005937

## Text-Extract

```

                                                            June 4, 2025

Marvin White
Chief Executive Officer
Aptevo Therapeutics Inc.
2401 4th Avenue, Suite 1050
Seattle, WA 98121

       Re: Aptevo Therapeutics Inc.
           Draft Registration Statement on Form S-1
           Submitted May 30, 2025
           CIK No. 0001671584
Dear Marvin White:

       This is to advise you that we do not intend to review your registration
statement.

       We request that you publicly file your registration statement at least
two business
days prior to the requested effective date and time. Please refer to Rules 460
and 461
regarding requests for acceleration. We remind you that the company and its
management are
responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review,
comments, action or absence of action by the staff.

       Please contact Jessica Dickerson at 202-551-8013 with any questions.

                                                            Sincerely,

                                                            Division of
Corporation Finance
                                                            Office of Life
Sciences
cc:   Sean Donahue, Esq.

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._